Modalis Pairs MDL-201 With Muscle-Targeted AAV
Exegenesis Bio and Modalis Therapeutics entered a research collaboration and license agreement giving Modalis access to EMC181, an engineered muscle-tropic, liver-detargeted adeno-associated virus capsid, for MDL-201. The program combines that capsid with Modalis’s CRISPR-GNDM…
